Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World
Through 3 years of follow-up, switching to B/F/TAF maintained high rates of virologic suppression in long-term PWH. These results were seen even in patients with preexisting NRTI RAMs.
Authors
- José Ignacio Bernardino (ORCID: https://orcid.org/0000-0003-3501-8529)
- Rosa de Miguel Buckley (ORCID: https://orcid.org/0000-0003-2749-818X)
- Lucía Serrano‐Luján (ORCID: https://orcid.org/0000-0001-7859-7992)
- Rocío Montejano (ORCID: https://orcid.org/0000-0002-3446-0545)
- Rafael Micán (ORCID: https://orcid.org/0000-0002-6626-4266)
- Marisa Montes (ORCID: https://orcid.org/0000-0003-1748-813X)
- Luis Ramos‐Ruperto (ORCID: https://orcid.org/0000-0001-5251-2161)
- José Ramón Arribas (ORCID: https://orcid.org/0000-0002-7410-9450)
- Cristina Marcelo (ORCID: https://orcid.org/0000-0002-6187-7442)
- Carmen Busca
- María del Mar Arcos-Rueda (ORCID: https://orcid.org/0000-0002-9961-5544)
- Luz Martı́n-Carbonero (ORCID: https://orcid.org/0000-0001-8102-4079)
- Alejandro de Gea Grela (ORCID: https://orcid.org/0000-0001-9316-8766)
- Juan González‐García (ORCID: https://orcid.org/0000-0002-3652-002X)
Institutions
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red (ES)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1093/ofid/ofaf087
- Citations
- 3
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.19